ARTICLE | Company News
Alexion other research news
October 9, 1995 7:00 AM UTC
The New Haven, Conn., company received a $750,000 Phase II SBIR grant from the National Heart, Lung and Blood Institute to develop its recombinant complement inhibitor, 5G1.1SC, to treat complications of cardiovascular surgery. ...